PMDA — authorised 22 January 2016
- Marketing authorisation holder: Astellas Pharma
- Status: approved
PMDA authorised Repatha on 22 January 2016
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Yes. PMDA authorised it on 22 January 2016.
Astellas Pharma holds the Japanese marketing authorisation.